Rothschild & Co Redburn Raises Merck Price Target, Maintains Neutral Rating

Key Facts

1Rothschild & Co Redburn increased its price target for Merck shares from $140 to $145.

2The research firm maintained a 'Neutral' rating on the pharmaceutical giant's stock.

As financial institutions re-evaluate the healthcare sector's potential, Rothschild & Co Redburn has increased its price target for Merck (MRK) from $140 to $145. This adjustment reflects an updated valuation of the pharmaceutical giant by the research firm, though it maintained a 'Neutral' rating on the stock. The move suggests a modest upward revision in fair value expectations without a fundamental shift in the overall investment thesis.

This revision comes as major pharmaceutical players face a competitive landscape; Merck recently reported strong momentum for its blockbuster drug Keytruda, while investors compare its performance against peers like Bristol-Myers Squibb and Pfizer. Per market data, MRK shares closed at $129.56 on July 2, 2026, implying that the new price target represents a potential upside of approximately 12% from that closing level.

Traders should monitor whether the stock holds above recent support levels near $125.99, the daily low recorded on July 2, 2026. In the absence of immediate sector-specific catalysts in the upcoming economic calendar, market participants will likely focus on regulatory news and pipeline developments as the primary drivers for reaching the analyst's revised target.